1.39
price down icon27.98%   -0.54
after-market Handel nachbörslich: 1.42 0.03 +2.16%
loading
Schlusskurs vom Vortag:
$1.93
Offen:
$1.79
24-Stunden-Volumen:
12.46M
Relative Volume:
6.12
Marktkapitalisierung:
$340.30M
Einnahmen:
$12.87M
Nettoeinkommen (Verlust:
$-114.34M
KGV:
-1.6077
EPS:
-0.8646
Netto-Cashflow:
$-79.23M
1W Leistung:
-16.27%
1M Leistung:
-13.13%
6M Leistung:
-30.85%
1J Leistung:
-51.57%
1-Tages-Spanne:
Value
$1.17
$1.79
1-Wochen-Bereich:
Value
$1.17
$1.95
52-Wochen-Spanne:
Value
$1.17
$4.32

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
Firmenname
Taysha Gene Therapies Inc
Name
Telefon
(214) 612-0000
Name
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
TSHA's Discussions on Twitter

Vergleichen Sie TSHA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
1.39 340.30M 12.87M -114.34M -79.23M -0.8646
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-04-09 Eingeleitet Piper Sandler Overweight
2023-02-01 Herabstufung Jefferies Buy → Hold
2023-01-27 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-11-09 Herabstufung Goldman Buy → Neutral
2022-03-09 Eingeleitet Robert W. Baird Outperform
2022-03-01 Eingeleitet Wells Fargo Overweight
2022-02-18 Eingeleitet SMBC Nikko Outperform
2021-12-16 Eingeleitet Guggenheim Buy
2021-07-16 Eingeleitet Needham Buy
2021-06-24 Eingeleitet Truist Buy
2021-06-15 Eingeleitet BTIG Research Buy
2021-06-09 Eingeleitet Wedbush Outperform
2021-06-08 Eingeleitet JMP Securities Mkt Outperform
2021-05-19 Eingeleitet Cantor Fitzgerald Overweight
2021-05-11 Fortgesetzt Jefferies Buy
2021-02-24 Eingeleitet William Blair Outperform
2021-01-05 Eingeleitet Oppenheimer Outperform
2020-10-19 Eingeleitet Chardan Capital Markets Buy
2020-10-19 Eingeleitet Goldman Buy
2020-10-19 Eingeleitet Jefferies Buy
2020-10-19 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten

pulisher
01:05 AM

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

01:05 AM
pulisher
11:51 AM

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga

11:51 AM
pulisher
11:23 AM

Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa

11:23 AM
pulisher
10:38 AM

Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com India

10:38 AM
pulisher
03:17 AM

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World

03:17 AM
pulisher
Mar 26, 2025

Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Mar 26, 2025
pulisher
Mar 19, 2025

Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? - Insider Monkey

Mar 19, 2025
pulisher
Mar 19, 2025

10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey

Mar 19, 2025
pulisher
Mar 14, 2025

Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com Australia

Mar 12, 2025
pulisher
Mar 11, 2025

Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 07, 2025
pulisher
Mar 07, 2025

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan

Mar 07, 2025
pulisher
Mar 03, 2025

TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Taysha Gene Therapies Reports 2024 Financial Results - TipRanks

Feb 27, 2025
pulisher
Feb 26, 2025

Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Taysha Gene Therapies reports FY24 EPS (36c) vs (96c) last year - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Taysha Gene Therapies Inc Reports Full Year 2024 EPS of -$0.36 a - GuruFocus.com

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings call transcript: Taysha Gene's Q4 2024 reports narrower loss, stock dips - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings call transcript: Taysha Gene’s Q4 2024 reports narrower loss, stock dips - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Taysha Gene Therapies, Inc. SEC 10-K Report - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

Can Taysha's Gene Therapy for Rett Syndrome Deliver? Key Safety Milestone Reached as Cash Extends to 2026 - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Feb 25, 2025
pulisher
Feb 21, 2025

Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

Taysha Gene Therapies to Release Full-Year 2024 Financial - GlobeNewswire

Feb 20, 2025
pulisher
Feb 19, 2025

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Gene Therapy Pioneer Taysha Readies Crucial 2024 Financial DisclosureHere's When - StockTitan

Feb 19, 2025
pulisher
Feb 17, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Brokerages - Defense World

Feb 17, 2025
pulisher
Feb 15, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by SG Americas Securities LLC - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3%Time to Buy? - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Feb 14, 2025
pulisher
Feb 12, 2025

Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Feb 12, 2025
pulisher
Feb 07, 2025

Taysha Gene Therapies Inc (TSHA) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Feb 07, 2025
pulisher
Feb 07, 2025

Taysha Gene Therapies Inc [TSHA] Records 50-Day SMA of $1.9835 - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

Taysha's Strategic Move: 491K Stock Options Awarded to Secure Top Industry Talent - StockTitan

Feb 07, 2025
pulisher
Feb 06, 2025

Rett Syndrome Market Growth Projections 2024-2034: - openPR

Feb 06, 2025
pulisher
Feb 06, 2025

Prepare Yourself for Liftoff: Taysha Gene Therapies Inc (TSHA) - SETE News

Feb 06, 2025

Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Kapitalisierung:     |  Volumen (24h):